| Budget Amount *help |
¥18,070,000 (Direct Cost: ¥13,900,000、Indirect Cost: ¥4,170,000)
Fiscal Year 2022: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2021: ¥6,760,000 (Direct Cost: ¥5,200,000、Indirect Cost: ¥1,560,000)
Fiscal Year 2020: ¥9,620,000 (Direct Cost: ¥7,400,000、Indirect Cost: ¥2,220,000)
|
|---|
| Outline of Final Research Achievements |
We identified a group of genes that cause quantitative changes in fibrosis-induced-pathogenic CD4+ T cells. We have generated a gene-deficient mouse and a reporter mouse for one of these genes. We found; (1) CD4+ T cells from the gene-deficient mouse were markedly reduced in the lungs. (2) CD4+ T cells expressing the gene were frequently infiltrated in the nasal polyps of human eosinophilic sinusitis patients. The results of this study not only revealed a new function of pathogenic helper T cells in pathogenesis, but also identified a new molecular mechanism for their regulation. Based on the results of this study, we will continue our research to elucidate new regulatory mechanisms of CD4+ T cells that are deeply involved in the pathogenesis of chronic inflammatory diseases and to form the technological basis for the development of novel therapies for intractable allergic airway diseases for which there is no curative treatment.
|
